Sepantronium bromide
Alternative Names: YM-155; YM155 monobromideLatest Information Update: 28 Jun 2025
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Naphthoquinones; Small molecules
- Mechanism of Action BIRC5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Breast cancer; Diffuse large B cell lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Ovarian cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 13 May 2022 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma presented at the 117th Annual Meeting of the American Urological Association